• Wegovy^® pill showed a mean weight loss of 16.6% in the OASIS 4 trial[1]
• Wegovy^® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events*
• Novo Nordisk expects to launch Wegovy^® pill in the US in early January 2026

Dubai, 24 December 2025- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy^® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.

Mike Doustdar, president and CEO of Novo Nordisk

Continue reading Wegovy® pill approved in the US as first oral GLP-1for weight management →